In this study, we constructed humanized A10 antibodies by CDR grafting with two human antibody frameworks, 8A7 and 16E816, to develop an applicable therapeutic agent for the treatment of patients with ADAMTS13-related bleeding disorder. The gene discussed is ADAMTS13; the disease is hemorrhagic disease.